Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
27.66
+0.52 (1.92%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Agios Pharmaceuticals Revenue
In the year 2024, Agios Pharmaceuticals had annual revenue of $36.50M with 36.07% growth. Agios Pharmaceuticals had revenue of $10.73M in the quarter ending December 31, 2024, with 51.06% growth.
Revenue (ttm)
$36.50M
Revenue Growth
+36.07%
P/S Ratio
43.05
Revenue / Employee
$74,791
Employees
488
Market Cap
1.58B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AGIO News
- 1 day ago - Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 - GlobeNewsWire
- 6 weeks ago - Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer - GlobeNewsWire
- 6 weeks ago - Agios to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 - GlobeNewsWire
- 2 months ago - Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint - GlobeNewsWire
- 2 months ago - Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 - GlobeNewsWire